keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/27926994/microvessels-of-the-heart-formation-regeneration-and-dysfunction
#1
Ioakim Spyridopoulos, Helen M Arthur
This issue of Microcirculation focusses on the special topic of "microvessels of the heart" and contains five state-of-the-art reviews and one expert article that reflect current efforts to address the major gaps in our understanding of these key microvessels. In the adult heart, most attention until recently (especially among the clinical cardiology community) has been given to the main coronary arteries, which are the culprit vessels in patients with coronary artery disease, including its most serious manifestation, acute myocardial infarction (MI)...
December 7, 2016: Microcirculation: the Official Journal of the Microcirculatory Society, Inc
https://www.readbyqxmd.com/read/27910282/eugene-robinson-keynote-speaker-for-2017-health-policy-conference
#2
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Journal of the American Association of Nurse Practitioners
https://www.readbyqxmd.com/read/27896938/population-pharmacokinetic-pharmacodynamic-modeling-of-tumor-size-dynamics-in-pembrolizumab-treated-advanced-melanoma
#3
M S Chatterjee, J Elassaiss-Schaap, A Lindauer, D C Turner, A Sostelly, T Freshwater, K Mayawala, M Ahamadi, J A Stone, R de Greef, A G Kondic, D P de Alwis
Pembrolizumab is a potent immune-modulating antibody active in advanced melanoma, as demonstrated in the KEYNOTE-001, -002, and -006 studies. Longitudinal tumor size modeling was pursued to quantify exposure-response relationships for efficacy. A mixture model was first developed based on an initial dataset from KEYNOTE-001 to describe four patterns of tumor growth and shrinkage. For subsequent analyses, tumor size measurements were adequately described by a single consolidated model structure that captured continuous tumor size with a combination of growth and regression terms, as well as a fraction of tumor responsive to therapy...
November 29, 2016: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/27870220/keynote-speakers
#4
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27863197/programmed-death-ligand-1-expression-and-response-to-the-anti-programmed-death-1-antibody-pembrolizumab-in-melanoma
#5
Adil I Daud, Jedd D Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S Weber, Antoni Ribas, F Stephen Hodi, Anthony M Joshua, Richard Kefford, Peter Hersey, Richard Joseph, Tara C Gangadhar, Roxana Dronca, Amita Patnaik, Hassane Zarour, Charlotte Roach, Grant Toland, Jared K Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S Peter Kang, Scot Ebbinghaus, Omid Hamid
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27863186/model-based-characterization-of-the-pharmacokinetics-of-pembrolizumab-a-humanized-anti-pd-1-monoclonal-antibody-in-advanced-solid-tumors
#6
M Ahamadi, T Freshwater, M Prohn, C H Li, D P de Alwis, R de Greef, J Elassaiss-Schaap, A Kondic, J A Stone
Pembrolizumab, a potent antibody against programmed death 1 (PD-1) receptor, has shown robust antitumor activity and manageable safety in patients with advanced solid tumors. Its pharmacokinetic (PK) properties were analyzed with population PK modeling using pooled data from the KEYNOTE-001, -002, and -006 studies of patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other solid tumor types. Pembrolizumab clearance was low and the volume of distribution small, as is typical for therapeutic antibodies...
November 14, 2016: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/27863143/using-model-based-learn-and-confirm-to-reveal-the-pharmacokinetics-pharmacodynamics-relationship-of-pembrolizumab-in-the-keynote-001-trial
#7
J Elassaiss-Schaap, S Rossenu, A Lindauer, S P Kang, R de Greef, J R Sachs, D P de Alwis
Evaluation of pharmacokinetic/pharmacodynamic (PK/PD) properties played an important role in the early clinical development of pembrolizumab. Because analysis of data from a traditional 3 + 3 dose-escalation design revealed several critical uncertainties, a model-based approach was implemented to better understand these properties. Based on anticipated scenarios for potency and PK nonlinearity, a follow-up study was designed and thoroughly evaluated. Execution of 14,000 virtual trials led to the selection and implementation of a robust design that extended the low-dose range by 200-fold...
November 8, 2016: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/27830225/troubled-waters-navigating-unintended-consequences-of-health-information-technology
#8
C U Lehmann, B Séroussi, M-C Jaulent
OBJECTIVES: To provide an introduction to the 2016 IMIA Yearbook of Medical Informatics by the editors. METHODS: We present a brief overview of the 2016 special topic "Unintended consequences of Health IT: new problems, new solutions", we review our choice of special topic section editors, and discuss the transitions in the editorial team for next year. RESULTS: This edition of the Yearbook acknowledges the fact that implementation and use of Health Information Technology (HIT) may result in unintended consequences, which may lead to both adverse and sometimes beneficial outcomes...
November 10, 2016: Yearbook of Medical Informatics
https://www.readbyqxmd.com/read/27815125/meeting-report-29th-international-conference-on-antiviral-research-in-la-jolla-ca-usa
#9
REVIEW
R Anthony Vere Hodge
The 29th International Conference on Antiviral Research (ICAR) was held in La Jolla, CA, USA from April 17 to 21, 2016. This report opens with a tribute to the late Chris McGuigan, a Past-President of ISAR, then continues with summaries of the principal invited lectures. Doug Richman (Elion Award) investigated HIV resistance, Bob Vince (Holý Award) showed how carbocyclic nucleoside analogs led to abacavir and Jerome Deval (Prusoff Award) explained how his group chose to seek a nucleoside analog to treat RSV...
November 1, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27807146/scientific-retreats-with-speed-dating-networking-to-stimulate-new-interdisciplinary-translational-research-collaborations-and-team-science
#10
Damayanthi Ranwala, Anthony J Alberg, Kathleen T Brady, Jihad S Obeid, Randal Davis, Perry V Halushka
To stimulate the formation of new interdisciplinary translational research teams and innovative pilot projects, the South Carolina Clinical and Translational Research (SCTR) Institute (South Carolina Clinical and Translational Science Award, CTSA) initiated biannual scientific retreats with 'speed dating' networking sessions. Retreat themes were prioritized based on the following criteria; cross-cutting topic, unmet medical need, generation of novel technologies and methodologies. Each retreat begins with an external keynote speaker followed by a series of brief research presentations by local researchers focused on the retreat theme, articulating potential areas for new collaborations...
November 2, 2016: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/27805897/scientific-overview-csci-citac-annual-general-meeting-and-young-investigators-forum-2015
#11
Eric Y Zhao, Tianwei Ellen Zhou, Matthew G K Benesch, Ayan Dey, Peter Liu, Patrick E Steadman, Kirill Zaslavsky, Raphael Schneider, Alexandra Kuzyk
The 2015 Annual General Meeting of The Canadian Society of Clinician Investigators (CSCI) and Clinician Investigator Trainee Association of Canada/Association des Cliniciens-Chercheurs en Formation du Canada (CITAC/ACCFC) was held in Toronto November 23-25, 2015, in conjunction with The University of Toronto Clinician Investigator Program Research Day. The theme for this year's meeting was "It takes a village" and the focus was the various support systems necessary to train a successful clinician scientist...
October 14, 2016: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/27770488/state-of-the-science-tools-and-measurement-for-shared-decision-making
#12
Karen R Sepucha, Maggie Breslin, Charles Graffeo, Christopher R Carpenter, Erik P Hess
Shared decision making (SDM) has been advocated as an approach to selecting medical tests and treatments for many situations. The goal of SDM is to ensure that patients are well informed, are meaningfully involved in decisions, and receive treatments that meet their goals and preferences. There is considerable evidence about the tools used to promote SDM, called patient decision aids, and many different measures have been developed to assess the impact of SDM. However, fairly little is known about the applicability of the tools and measures in the emergency department (ED) setting...
December 2016: Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine
https://www.readbyqxmd.com/read/27752453/the-2015-annual-meeting-of-setac-german-language-branch-in-zurich-7-10-september-2015-ecotoxicology-and-environmental-chemistry-from-research-to-application
#13
Inge Werner, Annette Aldrich, Benjamin Becker, Dennis Becker, Markus Brinkmann, Michael Burkhardt, Norbert Caspers, Sophie Campiche, Nathalie Chèvre, Rolf-Alexander Düring, Beate I Escher, Fabian Fischer, Sabrina Giebner, Katharina Heye, Henner Hollert, Marion Junghans, Cornelia Kienle, Katja Knauer, Muris Korkaric, Veronika Märkl, Jane Muncke, Jörg Oehlmann, Georg Reifferscheid, Daniel Rensch, Andreas Schäffer, Sabrina Schiwy, Simon Schwarz, Helmut Segner, Eszter Simon, Rita Triebskorn, Etiënne L M Vermeirssen, Thomas Wintgens, Markus Zennegg
This report provides a brief review of the 20th annual meeting of the German Language Branch of the Society of Environmental Toxicology and Chemistry (SETAC GLB) held from September 7th to 10th 2015 at ETH (Swiss Technical University) in Zurich, Switzerland. The event was chaired by Inge Werner, Director of the Swiss Centre for Applied Ecotoxicology (Ecotox Centre) Eawag-EPFL, and organized by a team from Ecotox Centre, Eawag, Federal Office of the Environment, Federal Office of Agriculture, and Mesocosm GmbH (Germany)...
2016: Environmental Sciences Europe
https://www.readbyqxmd.com/read/27745820/carboplatin-and-pemetrexed-with-or-without-pembrolizumab-for-advanced-non-squamous-non-small-cell-lung-cancer-a-randomised-phase-2-cohort-of-the-open-label-keynote-021-study
#14
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi
BACKGROUND: Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC...
October 10, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27718847/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer
#15
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy...
October 8, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27710038/9th-annual-symposium-on-self-monitoring-of-blood-glucose-april-28-30-2016-madrid-spain
#16
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Madrid, Spain, for the 9th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts, thus facilitating new collaborations and research projects to improve the lives of people with diabetes. The 2016 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27701388/patterns-of-response-to-anti-pd-1-treatment-an-exploratory-comparison-of-four-radiological-response-criteria-and-associations-with-overall-survival-in-metastatic-melanoma-patients
#17
Leila Khoja, Minnie Kibiro, Ur Metser, Craig Gedye, David Hogg, Marcus O Butler, Eshetu G Atenafu, Anthony M Joshua
BACKGROUND: Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by response evaluation (RECIST) 1.1, immune-related response criteria (irRC), CHOI and modified CHOI (mCHOI) and correlated response with overall survival (OS). METHODS: Thirty-seven patients with 567 measurable lesions treated with pembrolizumab in the Keynote 001 trial were studied. Association of response with OS was determined...
November 8, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27697977/emerging-issues-and-opportunities-in-health-information-technology
#18
Elizabeth A Nardi, Lisa Korin Lentz, Katherine Winckworth-Prejsnar, Amy P Abernethy, Robert W Carlson
When used effectively, health information technology (HIT) can transform clinical care and contribute to new research discoveries. Despite advances in HIT and increased electronic health record adoption, many challenges to optimal use, interoperability, and data sharing exist. Data standardization across systems is limited, and scanned medical note documents result in unstructured data that make reporting on quality measures for reimbursement burdensome. Different policies and initiatives, including the Health Information Technology for Economic and Clinical Health Act, the Medicare Access and CHIP Reauthorization Act, and the National Cancer Moonshot initiative, among others, all recognize the impact that HIT can have on cancer care...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27689065/asia-prostate-cancer-study-a-cap-study-launch-symposium
#19
Hideyuki Akaza, Yoshihiko Hirao, Choung-Soo Kim, Mototsugu Oya, Seiichiro Ozono, Dingwei Ye, Matthew Cooperberg, Shiro Hinotsu, Ji Youl Lee, Gang Zhu, Mikio Namiki, Shigeo Horie, Byung Ha Chung, Chung-Hsin Chen, Ng Chi Fai, Lukman Hakim, Edmund Chiong, Jason Letran, Rainy Umbas, Kazuhiro Suzuki, Kazuo Nishimura, Teng Aik Ong, Bannakij Lojanapiwat, Tong-Lin Wu, Wun-Jae Kim, Declan Murphy, Osamu Ogawa, Peter Carroll, Seiji Naito, Taiji Tsukamoto
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The A-CaP Study is scheduled to begin in 2016, when each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognosis investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea...
September 2016: Prostate International
https://www.readbyqxmd.com/read/27687748/use-of-twitter-polls-to-determine-public-opinion-regarding-content-presented-at-a-major-national-specialty-society-meeting
#20
Andrew B Rosenkrantz, C Matthew Hawkins
PURPOSE: The aim of this study was to evaluate the feasibility of using Twitter polls to assess public opinion regarding session content at a national specialty society meeting. METHODS: Twitter polls allow users to embed multiple-choice questions within tweets and automatically aggregate responses. Two radiologists attending the 2016 annual meeting of the ACR posted a Twitter poll containing the hashtag #ACR2016 during 10 meeting sessions addressing socioeconomics/advocacy, patient experience, and social media/informatics (20 polls total)...
September 24, 2016: Journal of the American College of Radiology: JACR
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"